vs
Side-by-side financial comparison of Lanvin Group Holdings Ltd (LANV) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Lanvin Group Holdings Ltd is the larger business by last-quarter revenue ($144.1M vs $103.7M, roughly 1.4× Twist Bioscience Corp).
Lanvin is a French luxury fashion house founded in 1889 by Jeanne Lanvin in Paris. It is the oldest French fashion house still in operation. Since 2018, it has been a subsidiary of Shanghai-based Lanvin Group. Lanvin Group includes Lanvin, Sergio Rossi, Wolford, St. John Knits, and Caruso.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
LANV vs TWST — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $144.1M | $103.7M |
| Net Profit | — | $-30.5M |
| Gross Margin | 53.9% | 52.0% |
| Operating Margin | -60.5% | -31.7% |
| Net Margin | — | -29.4% |
| Revenue YoY | — | 16.9% |
| Net Profit YoY | — | 3.4% |
| EPS (diluted) | — | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $103.7M | ||
| Q2 25 | $144.1M | — | ||
| Q2 24 | $184.7M | — | ||
| Q2 23 | $231.7M | — |
| Q4 25 | — | $-30.5M | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | 52.0% | ||
| Q2 25 | 53.9% | — | ||
| Q2 24 | 57.5% | — | ||
| Q2 23 | 58.5% | — |
| Q4 25 | — | -31.7% | ||
| Q2 25 | -60.5% | — | ||
| Q2 24 | -35.0% | — | ||
| Q2 23 | -32.5% | — |
| Q4 25 | — | -29.4% | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | $-0.50 | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $32.1M | $197.9M |
| Total DebtLower is stronger | $290.3M | — |
| Stockholders' EquityBook value | $-116.4M | $456.1M |
| Total Assets | $632.1M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q2 25 | $32.1M | — | ||
| Q2 24 | $19.3M | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q2 25 | $290.3M | — | ||
| Q2 24 | $136.4M | — | ||
| Q2 23 | — | — |
| Q4 25 | — | $456.1M | ||
| Q2 25 | $-116.4M | — | ||
| Q2 24 | $100.1M | — | ||
| Q2 23 | — | — |
| Q4 25 | — | $638.1M | ||
| Q2 25 | $632.1M | — | ||
| Q2 24 | $731.8M | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | 1.36× | — | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-75.1K | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-24.8M | ||
| Q2 25 | $-75.1K | — | ||
| Q2 24 | $-36.2K | — | ||
| Q2 23 | $-62.8K | — |
| Q4 25 | — | $-34.8M | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | -33.5% | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | 9.6% | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LANV
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
